News
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis),
The FDA has identified critical lapses at a production facility operated by Novo Nordisk that is used by several drugmakers, ...
Despite boasting a new owner, the Indiana manufacturing plant that Novo Nordisk picked up as part of its parent company's ...
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.
Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback